SECsense Logo

Entrada Therapeutics, Inc. 8-K Report: Key Shareholder Updates on February 24, 2025

$TRDA
Form 8-K
Filed on: 2025-02-24
Source
Entrada Therapeutics, Inc. 8-K Report: Key Shareholder Updates on February 24, 2025

Here is the extracted key information from the provided SEC filing section:

  1. Filing Type: The document is an 8-K filing, which is used to report significant events that shareholders should know about.
  2. Company Information:
  • Name: Entrada Therapeutics, Inc.
  • CIK: 0001689375
  • SEC Central Index Key (CIK): 0001689375
  • IRS Employer Identification Number (EIN): 81-3983399
  • Address: One Design Center Place, Suite 17-500, Boston, MA 02210
  • Phone Number: (857) 520-9158
  1. Stock Information:
  • Common Stock Par Value: $0.0001 per share
  • Stock Symbol: TRDA
  • Exchange: NASDAQ
  1. Reporting Period:
  • Filing Date: February 24, 2025
  • Period Covered: The filing pertains to the date of February 24, 2025.
  1. XBRL Information:
  • The document is formatted in XBRL (eXtensible Business Reporting Language), which is used for the electronic transmission of business and financial data.

Insights:

  • The filing indicates that Entrada Therapeutics, Inc. is actively reporting to the SEC, suggesting it is a publicly traded company with obligations to disclose material information.
  • The date of the report (February 24, 2025) suggests that the information is current and may relate to significant business developments or events occurring on that date.
  • The presence of the 8-K filing indicates that there may have been a significant event that warranted immediate reporting to shareholders.
  • The company is listed on NASDAQ, which may imply a certain level of credibility and adherence to regulatory requirements expected from public companies.

This information is crucial for investors and analysts monitoring the company's activities and financial health.